Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Ad26

- PMLiVE

Gilead’s New Drug Application for Yeztugo accepted by US FDA

The investigational once-weekly oral treatment could be the first long-acting pill for HIV prevention

- PMLiVE

Johnson & Johnson files FDA application for Tremfya in psoriatic arthritis

Approximately 125 million people globally are living with some form of psoriasis

- PMLiVE

Gilead Sciences’ Biktarvy granted FDA approval for expanded HIV use

An estimated 1.2 million people in the US are currently living with the virus

- PMLiVE

Johnson & Johnson’s TAR-200 granted FDA priority review to treat bladder cancer

An estimated 84,870 people will be diagnosed with bladder cancer in the US this year

- PMLiVE

Gilead Sciences’ twice-yearly HIV PrEP drug Yeztugo granted FDA approval

More than 100 people in the US were diagnosed with HIV every day in 2023

- PMLiVE

Johnson & Johnson’s Tremfya granted EC approval to treat ulcerative colitis in adults

More than 2.5 million people in Europe are living with the inflammatory bowel disease

- PMLiVE

J&J’s Stelara granted EC approval to treat Crohn’s disease in paediatric patients

Approximately 25% of cases are diagnosed during childhood or adolescence

- PMLiVE

Johnson & Johnson’s Tremfya recommended by CHMP to treat Crohn’s disease

Inflammatory bowel disease is estimated to affect nearly two million people across Europe

- PMLiVE

J&J shares overall survival results for Rybrevant/Lazcluze combination in lung cancer

The regimen was approved by the MHRA earlier this month to treat EGFR-mutated NSCLC

- PMLiVE

Johnson & Johnson to invest more than $55bn in US over next four years

The commitment marks a 25% increase to the company's US investments in the past four years

- PMLiVE

Johnson & Johnson’s Tremfya granted FDA approval to treat Crohn’s disease

An estimated three million people in the US are affected by inflammatory bowel disease

- PMLiVE

J&J/Protagonist’s icotrokinra shows promise in phase 3 plaque psoriasis programme

More than 125 million people worldwide are estimated to be living with the immune-mediated skin disease

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links